Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.89 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16361558 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL21779332 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL10322552 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL16774365 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19464922 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL31061297 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL29524299 | 1.00 | ADORA3 (1.00) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19459897 | 0.95 | ADORA3 (0.91) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19799157 | 0.95 | ADORA3 (0.91) | ADORA3KCNH2ABCG2ADORA2AADORA1 | |
| SCHEMBL19464859 | 0.94 | ADORA3 (0.89) | ADORA3KCNH2ABCG2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| EP-3074398-B1 | A3 ADENOSINE RECEPTOR AGONISTS | US HEALTH (US) | 2021-03-17 | — | — | EP | disclosed |
| US-9963450-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885KCNH2 3479/4885ABCG2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.